Effect of the Uriclarity Program on Perceived Milk Supply in Postpartum Women in Piura-Peru
Launched by CRIANZAMOR · Feb 26, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a program called the Uriclarity Program to see if it helps new mothers in Piura, Peru, feel more confident about their milk supply when breastfeeding. Many women worry that they don’t have enough milk for their babies, which can affect their confidence and ability to stick to exclusive breastfeeding. The study will compare the Uriclarity Program with standard support for breastfeeding to find out which is more helpful for mothers in this situation.
To be part of the trial, women must be new mothers who have recently given birth (within 24-48 hours) and are exclusively breastfeeding. They should also have completed at least primary school and be comfortable using a smartphone with WhatsApp for follow-up support. Participants will receive either the Uriclarity Program or standard breastfeeding advice shortly after delivery and will be checked in on at different points during the first two weeks after giving birth to see how their feelings about milk supply change. This study aims to provide valuable information on whether this new program can help mothers feel better about breastfeeding and support them in exclusively breastfeeding their babies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Postpartum women within 24-48 hours after delivery (vaginal or cesarean).
- • Term neonates (37-41 weeks of gestation).
- • Exclusive breastfeeding at enrollment.
- • Maternal education level of at least primary school completed.
- • Ability to use a smartphone with WhatsApp for follow-up support.
- Exclusion Criteria:
- • Maternal conditions that may affect breastfeeding, such as flat or inverted nipples, diabetes, hypertension, or morbid obesity.
- • Maternal medication with effects on lactation.
- • Cigarette smoking.
- • Neonatal conditions impacting breastfeeding, including congenital heart defects, cleft lip/palate, or ankyloglossia.
- • Use of infant formula, pacifiers, or bottles before enrollment.
- • Diagnosed maternal or neonatal illness after study enrollment that may interfere with breastfeeding.
- • Newborns who experienced hypoglycemia, weight loss equal to or greater than 7%, or any condition related to breastfeeding failure during their hospital stay.
About Crianzamor
Crianzamor is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapies. With a focus on neurological and psychiatric conditions, Crianzamor collaborates with healthcare professionals, academic institutions, and regulatory bodies to ensure the highest standards of safety and efficacy in clinical trials. Committed to transparency and ethical practices, the organization aims to accelerate the development of groundbreaking treatments, fostering a comprehensive understanding of disease mechanisms and therapeutic interventions. Through its rigorous research initiatives, Crianzamor strives to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Piura, , Peru
Piura, Chulucanas, Peru
Patients applied
Trial Officials
Jackeline Ashiyama Vega, NP
Principal Investigator
Crianzamor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported